Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review

Paulina Orzechowska; Gabriela Budziszewska; Aneta Dziurdź; Katarzyna Majewska; Gabriela Mastej-Witek; Aleksandra Kielan; Aleksandra Bartkowska; Paulina Głowacka; Alicja Okupniak; Aleksandra Łupicka

doi:10.2478/bgbl-2026-0014

.blurhash-client-img { display: none !important; }

Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review

Biuletyn Głównej Biblioteki Lekarskiej

Volume 59 (2026): Issue 387 (December 2026)

By: Paulina Orzechowska , Gabriela Budziszewska , Aneta Dziurdź , Katarzyna Majewska , Gabriela Mastej-Witek , Aleksandra Kielan , Aleksandra Bartkowska , Paulina Głowacka , Alicja Okupniak and Aleksandra Łupicka

Open Access

|Sep 2026

Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Mørch LS. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12268. doi: 10.1002/trc2.12268. PMID: 35229024; PMCID: PMC8864443.
Open DOI Search in Google Scholar Open in PubMed Back to article
Grieco M, Giorgi A, Gentile MC, d’Erme M, Morano S, Maras B, Filardi T. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019 Oct 18;13:1112. doi: 10.3389/fnins.2019.01112. PMID: 31680842; PMCID: PMC6813233.
Open DOI Search in Google Scholar Open in PubMed Back to article
Tseng PT, Zeng BY, Hsu CW, Hung CM, Carvalho AF, Stubbs B, Chen YW, Chen TY, Lei WT, Chen JJ, Su KP, Shiue YL, Liang CS. The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis. BMC Med. 2025 Apr 7;23(1):197. doi: 10.1186/s12916-025-04018-w. PMID: 40189519; PMCID: PMC11974209.
Open DOI Search in Google Scholar Open in PubMed Back to article
Messak M, Abdelmageed A, Senbel AA, Khattab YA, Mandour Y, Shaker O, Rehan AH, Oransa S, Nasr M, Shabeeb AE, Rezq Z, Hossam F, Abouelmagd ME. Efficacy and safety of GLP-1 agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9721–9736. doi: 10.1007/s00210-025-03932-3. Epub 2025 Mar 11. PMID: 40067438; PMCID: PMC12350457.
Open DOI Search in Google Scholar Open in PubMed Back to article
Nogueira LOS, Mazetto RASV, Defante MLR, Antunes VLJ, Gonçalves OR, Corso AMS, Coletta MVD, Boone DL, Machado Filho WS, Borges V, Ferraz HB. Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson’s disease: a systematic review and meta-analysis. Arq Neuropsiquiatr. 2025 Apr;83(4):1–10. doi: 10.1055/s-0045-1806824. Epub 2025 Apr 27. PMID: 40288416; PMCID: PMC12034413.
Open DOI Search in Google Scholar Open in PubMed Back to article
Bi Z, Wang L, Wang W. Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer’s disease: A systematic review and meta-analysis. Adv Clin Exp Med. 2023 Nov;32(11):1223–1231. doi: 10.17219/acem/161734. PMID: 37077141.
Open DOI Search in Google Scholar Open in PubMed Back to article
Ballum H, Dri C, Liao S, Yu M, Le GH, Wong S, Teopiz KM, Kwan ATH, Ho R, Choi H, Rosenblat JD, Vinberg M, K Y Lo H, McIntyre RS. The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses. J Affect Disord. 2026 Jun 1;402:121310. doi: 10.1016/j.jad.2026.121310. Epub 2026 Jan 30. PMID: 41621451.
Open DOI Search in Google Scholar Open in PubMed Back to article
Abou Elezz AM, Khalefa K, Gadelmawla AF, Khattab YA, Abo Zeid M. Antidiabetic drugs in Parkinson’s disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation. Inflammopharmacology. 2025 Aug;33(8):4577–4593. doi: 10.1007/s10787-025-01873-0. Epub 2025 Aug 5. PMID: 40762930; PMCID: PMC12397177.
Open DOI Search in Google Scholar Open in PubMed Back to article
Tseng PT, Zeng BY, Hsu CW, Hung CM, Carvalho AF, Stubbs B, Chen YW, Chen TY, Lei WT, Chen JJ, Su KP, Shiue YL, Liang CS. The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis. BMC Med. 2025 Apr 7;23(1):197. doi: 10.1186/s12916-025-04018-w. PMID: 40189519; PMCID: PMC11974209.
Open DOI Search in Google Scholar Open in PubMed Back to article
Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci. 2022 Jan 10;23(2):739. doi: 10.3390/ijms23020739. PMID: 35054924; PMCID: PMC8775408.
Open DOI Search in Google Scholar Open in PubMed Back to article
Xu T, Zheng YJ, Wong S, Dri CE, Zhou XT, Teopiz KM, Le GH, McIntyre RS. Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: A systematic review. Asian J Psychiatr. 2026 Mar;117:104870. doi: 10.1016/j.ajp.2026.104870. Epub 2026 Jan 29. PMID: 41619567.
Open DOI Search in Google Scholar Open in PubMed Back to article
Luo Y, Xia Y, Gong X, Hao M, Wei Q, Liao L. GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential. BMC Ophthalmol. 2026 Jan 8;26(1):12. doi: 10.1186/s12886-025-04559-x. PMID: 41501669; PMCID: PMC12781364.
Open DOI Search in Google Scholar Open in PubMed Back to article
Yeh JA, Lin SM, Liu YC, Hsu JZ, Huang AH, Munir KM, Peng CC, Loh CH, Huang HK. Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson’s disease in patients with type 2 diabetes: A propensity score-matched cohort study with meta-analysis. Diabetes Res Clin Pract. 2025 Nov;229:112914. doi: 10.1016/j.diabres.2025.112914. Epub 2025 Sep 19. PMID: 40976497.
Open DOI Search in Google Scholar Open in PubMed Back to article
Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M. Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis. Clin Ther. 2026 Apr;48(4):347–384. doi: 10.1016/j.clinthera.2026.02.010. Epub 2026 Mar 19. PMID: 41862354.
Open DOI Search in Google Scholar Open in PubMed Back to article
Erbil D, Eren CY, Demirel C, Küçüker MU, Solaroğlu I, Eser HY. GLP-1’s role in neuroprotection: a systematic review. Brain Inj. 2019;33(6):734–819. doi: 10.1080/02699052.2019.1587000. Epub 2019 Apr 2. PMID: 30938196.
Open DOI Search in Google Scholar Open in PubMed Back to article
Zhang Y, Wang C, Wang Y, Wang T. Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2025 Aug 4;272(9):555. doi: 10.1007/s00415-025-13301-y. PMID: 40760123.
Open DOI Search in Google Scholar Open in PubMed Back to article
Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC. GLP-1 receptor agonists for Parkinson’s disease. Cochrane Database Syst Rev. 2020 Jul 23;7(7):CD012990. doi: 10.1002/14651858.CD012990.pub2. PMID: 32700772; PMCID: PMC7390475.
Open DOI Search in Google Scholar Open in PubMed Back to article
Badran AS, Gbreel MI. From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson’s disease. A systematic review and meta-analysis of placebo-controlled trials. Neurol Sci. 2025 Nov;46(11):5643–5655. doi: 10.1007/s10072-025-08411-4. Epub 2025 Aug 21. PMID: 40835782.
Open DOI Search in Google Scholar Open in PubMed Back to article
Sioufi MC, Heroiu I, Wong S, Le GH, Dri CE, Zheng YJ, Teopiz KM, Rhee TG, Lo HKY, Guillen-Burgos HF, McIntyre RS. The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents. Acta Neuropsychiatr. 2026 Feb 13;38:e24. doi: 10.1017/neu.2026.10060. PMID: 41684077.
Open DOI Search in Google Scholar Open in PubMed Back to article
Helal MM, AbouShawareb H, Abbas OH, Haddad R, Zain Y, Osman ASA, Hassan AK. GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis. Diabetol Metab Syndr. 2025 Aug 23;17(1):352. doi: 10.1186/s13098-025-01888-1. PMID: 40849485; PMCID: PMC12374370.
Open DOI Search in Google Scholar Open in PubMed Back to article
Albuquerque MB, Nunes LEDB, Oliveira Maldonado JV, Melo Ferreira DG, Margato MM, Rabelo LV, Valença MM, Oliveira Cordeiro LH. GLP-1 receptor agonists for Parkinson’s disease: An updated meta-analysis. Parkinsonism Relat Disord. 2025 Jan;130:107220. doi: 10.1016/j.parkreldis.2024.107220. Epub 2024 Nov 29. PMID: 39642803.
Open DOI Search in Google Scholar Open in PubMed Back to article
Wang SY, Wu SL, Chen TC, Chuang CS. Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis. Int J Environ Res Public Health. 2020 Jul 3;17(13):4805. doi: 10.3390/ijerph17134805. PMID: 32635358; PMCID: PMC7369739.
Open DOI Search in Google Scholar Open in PubMed Back to article
Tang H, Zhang B, Lu Y, Donahoo WT, Singh Ospina N, Kotecha P, Lu Y, Tong J, Smith SM, Rosenberg EI, Kimmel SE, Bian J, Guo J, Chen Y. Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials. Diabetes Obes Metab. 2025 Mar;27(3):1444–1455. doi: 10.1111/dom.16147. Epub 2024 Dec 26. PMID: 39723481; PMCID: PMC12135018.
Open DOI Search in Google Scholar Open in PubMed Back to article
O’Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S, Le NPM, Liew A, Migliore M, Mekary RA. The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer’s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2026 Jan 12;47(1):149. doi: 10.1007/s10072-025-08602-z. PMID: 41524953.
Open DOI Search in Google Scholar Open in PubMed Back to article
Leta V, Ray Chaudhuri K, Milner O, Chung-Faye G, Metta V, Pariante CM, Borsini A. Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence. Brain Behav Immun. 2021 Nov;98:59–73. doi: 10.1016/j.bbi.2021.07.026. Epub 2021 Aug 5. PMID: 34364965.
Open DOI Search in Google Scholar Open in PubMed Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/bgbl-2026-0014 | Journal eISSN: 2956-6851 | Journal ISSN: 0373-174X

Journal RSS Feed

Language: English, Polish

Page range: 49 - 64

Submitted on: Aug 3, 2026

Accepted on: Aug 24, 2026

Published on: Sep 18, 2026

Published by: The Medical Library named after S. Konopka in Warsaw

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

glucagon-like peptide-1 receptor agonists,

Related subjects:

Biomedical engineering

© 2026 Paulina Orzechowska, Gabriela Budziszewska, Aneta Dziurdź, Katarzyna Majewska, Gabriela Mastej-Witek, Aleksandra Kielan, Aleksandra Bartkowska, Paulina Głowacka, Alicja Okupniak, Aleksandra Łupicka, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 59 (2026): Issue 387 (December 2026)